<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing<sup>177</sup>Lu-PSMA-I&T Therapy-Reference-Cited by-同舟云学术

¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing¹⁷⁷Lu-PSMA-I&T Therapy

Published:2022-09-08 Issue:3 Volume:64 Page:410-415
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

John Nikeith,Pathmanandavel Sarennya,Crumbaker Megan,Counter William,Ho Bao,Yam Andrew O.,Wilson Peter,Niman Remy,Ayers Maria,Poole Aron,Hickey Adam,Agrawal Shikha,Perkins Gary,Kallinen Annukka,Eslick Enid,Stockler Martin R.,Joshua Anthony M.,Nguyen Andrew,Emmett Louise

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference21 articles.

1. Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

2. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet.,2021

3. Sartor O de Bono J Chi KN . Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–1103.

4. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

5. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer;Clinical and Translational Oncology;2024-09-12

2. Impact of Posttreatment SPECT/CT on Patient Management During¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy;Journal of Nuclear Medicine;2024-08-08

3. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

4. Treatment Response Imaging in Prostate Cancer;PET Clinics;2024-07

5. Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection;Journal of Nuclear Medicine;2024-05-09